Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite ...

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Explore more details here.

Rowe Price’s large analyst team has the breadth ... The strategy’s tendency to stay close to the benchmark’s sector weightings means stock selection has done the heavy lifting.

2-Year U.S. Treasury Note Continuous Contract $102.863-0.023-0.02% 5-Year U.S. Treasury Note Continuous Contract $106.523 0.023 0.02% 10-Year U.S. Treasury Note Continuous Contract $109.094 0.063 ...

Don’t get trapped in rigid guidelines that stifle your authentic expression; they’ll only dull the brilliance of your creativity. If you dilute your ideas to fit into a predefined box, your ...

Take a moment to evaluate where your energy, time, and resources are truly going in your career zone. Are they aligned with your goals and the life you’re trying to build, or are they slipping ...